Gujarat FDCA: Manufacturing license granted to Glenmark for producing API for antiviral drug favipiravir

Glenmark Pharmaceuticals has been granted manufacturing license by the Gujarat Food and Drug Control Administration (FDCA) for producing API for the antiviral drug favipiravir at its Ankleshwar plant based on Drugs Controller General of India (DCGI)’s approval to manufacture favipiravir for mild and moderate COVID-19 patients in the country.

Dr H G Koshia said that, “It is a new drug in India for mild COVID-19 treatment. Company’s tableting unit is in Himachal Pradesh at Baddi. Post production of the API in Ankleshwar, the API will go for tableting and the drug will be available pan India in a couple of days time based on my correspondence with the company. We fast tracked the license approval based on DCGI permission to Glenmark Pharmaceuticals for commercial production of the drug favipiravir.

Strong clinical evidences has shown results that Favipiravir helps in treating patients having symptoms from mild to moderate. It offers broad spectrum RNA virus coverage with clinical improvement noted across age groups 20 to >90 years. The drug can also be used in the treatment of COVID-19 patients with co-morbid conditions such as diabetes and heart disease with mild to moderate COVID-19 symptoms. The antiviral drug reduces the viral load within 4 days and provides faster symptomatic and radiological improvement.
Glenmark filed the product for clinical trial with India’s drug regulator DCGI and became the first pharmaceutical company in India to receive approval for conducting phase 3 clinical trial on mild to moderate COVID-19 patients.

Favipiravir has been approved in Japan since 2014 for the treatment of novel or re-emerging influenza virus infections. It is converted into an active phosphoribosylated form (favipiravir-RTP) in cells and recognized as a substrate by viral RNA polymerase, thereby inhibiting RNA polymerase activity.

  • Related Posts

    MedTech Zone AMTZ Puts Vizag on the Science Map of India

    Vizag Science &Technology Cluster rated as one of the India’s Strategic Innovation Hubs Visakhapatnam, June 28 – In a significant boost to Vizag’s growing scientific stature, the Andhra Pradesh MedTech…

    • Health
    • June 11, 2025
    • 489 views
    Doctors trialling ‘poo pills’ to flush out dangerous superbugs

    UK doctors are attempting to clear dangerous superbug infections using “poo pills” containing freeze-dried faeces. The stool samples come from healthy donors and are packed with good bacteria. Early data…

    Leave a Reply

    Your email address will not be published. Required fields are marked *

    You Missed

    Nectar to sell API, formulations & menthol biz to Ceph Lifesciences for Rs 1,290 cr

    Nectar to sell API, formulations & menthol biz to Ceph Lifesciences for Rs 1,290 cr

    Flush these 17 expired medicines now. India’s top drug regulatory body issues stern warning

    Flush these 17 expired medicines now. India’s top drug regulatory body issues stern warning

    Sun Pharma confirms the stocks of ‘Levipil 500’ seized by Telangana DCA in raids is spurious

    Sun Pharma confirms the stocks of ‘Levipil 500’ seized by Telangana DCA in raids is spurious

    HC-ordered expert panel for weight loss drug may be set up by mid-July

    HC-ordered expert panel for weight loss drug may be set up by mid-July